Trial · NCT07898475
In Vitro Susceptibility of Dermatophytes to Terbinafine and Itraconazole: MIC Distributions and Elevated-MIC Isolates in Faisalabad, Pakistan
NCT07898475, Recruiting, Dr. Amara Safdar
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. In Vitro Susceptibility of Dermatophytes to Terbinafine and Itraconazole: MIC Distributions and Elevated-MIC Isolates in Faisalabad, Pakistan. Trials, record NCT07898475. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07898475
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- In Vitro Susceptibility of Dermatophytes to Terbinafine and Itraconazole: MIC Distributions and Elevated-MIC Isolates in Faisalabad, Pakistan
- NCT number
- NCT07898475
- Status
- Recruiting
- Enrollment
- 120 participants, estimated
- Lead sponsor
- Dr. Amara Safdar
- Conditions
- Dermatophytosis, Tinea Corporis, Tinea Cruris, Tinea Pedis, Onychomycosis
- Interventions
- In vitro antifungal susceptibility testing
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Trichophyton isolates with elevated terbinafine MIC | Up to 7 weeks after specimen collection | Percentage of evaluable Trichophyton isolates with a terbinafine minimum inhibitory concentration (MIC) of 0.5 ug/mL or higher (study-defined elevated MIC), determined by CLSI M38 broth microdilution with an 80% inhibition endpoint, reported with a Wilson 95% confidence interval. |
| Secondary | Terbinafine MIC distribution, range, MIC50 and MIC90 | Up to 7 weeks after specimen collection | Terbinafine MIC values (ug/mL) of all dermatophyte isolates, reported by species. |
| Secondary | Itraconazole MIC distribution, range, MIC50 and MIC90 | Up to 7 weeks after specimen collection | Itraconazole MIC values (ug/mL) of all dermatophyte isolates, reported descriptively by species. |
| Secondary | Species distribution of dermatophyte isolates | Up to 4 weeks after specimen collection | Number and percentage of isolates of each dermatophyte species or complex, identified by culture morphology and lactophenol cotton blue mount. |
| Secondary | Association of elevated terbinafine MIC with clinical variables | Up to 7 weeks after specimen collection | Proportion of Trichophyton isolates with elevated terbinafine MIC compared across clinical type, disease duration (less than 6 vs 6 months or longer), previous antifungal use (none, topical only, systemic) and topical corticosteroid use, using chi-square or Fisher's exact test (exploratory). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07898475
GET https://conductscience.org/api/trials/v1/NCT07898475/registered